{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000048","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.923850+00:00","generated_at":"2026-06-09T08:36:20.841348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Novocure Q3 net revenues $127.3M (-3% YoY); net loss $49.5M as INNOVATE-3 misses endpoint","bullets":["Net revenues $127.3M, down 3% YoY; US contributed $86.2M, Germany $14.7M, Japan $7.6M.","Net loss $49.5M ($0.46 loss per share); adjusted EBITDA $(29.1)M.","3,639 active patients on therapy as of Sept 30, 2023; prescriptions up 6% YoY to 1,467.","Phase 3 INNOVATE-3 (ovarian cancer) did not meet primary overall survival endpoint at final analysis.","Cash & short-term investments $921.2M; gross margin 75%."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000048","json":"https://secwatch.observer/filing/0001645113-23-000048.json","markdown":"https://secwatch.observer/filing/0001645113-23-000048.md","text":"https://secwatch.observer/filing/0001645113-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/0001645113-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/nvcr-20231026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:36:20.841348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7917f37a13a1912614990194d964767267ae7106","claim":"NovoCure Ltd reported the quarter ended September 30, 2023 results: revenue $127.3 million, net income Net loss for the quarter was $49.5 million with loss per share of $0.46, EPS $0.46.","evidence_excerpt":"Total net revenues for the quarter were $127.3 million, a decrease of 3% compared to the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/0001645113-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$127.3 million"},{"label":"Net income","value":"Net loss for the quarter was $49.5 million with loss per share of $0.46"},{"label":"EPS","value":"$0.46"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}